By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Napo Pharmaceuticals, Inc. 

185 Berry Street
Suite 1300
South San Francisco  California  94080  U.S.A.
Phone: 415-371-8300 Fax: 415-371-8311



Company News
Napo Pharmaceuticals, Inc. Release: New Data Shows Dramatic Reduction In Chronic Diarrhea Episodes With Crofelemer (Mytesi) Treatment 7/24/2017 8:25:22 AM
Jaguar Animal Health To Hold Special Meeting Of Stockholders July 27, 2017 To Vote Upon The Consummation Of Its Proposed Merger With Napo Pharmaceuticals, Inc. 7/7/2017 7:01:43 AM
Jaguar Animal Health And Napo Pharmaceuticals, Inc. Announce Filing Of Two Orphan Drug Designation Applications With FDA For Mytesi For Serious Unmet Medical Needs 6/5/2017 2:18:36 PM
Napo Pharmaceuticals, Inc.’ New Mytesi Video Calls Attention To The Continuing Widespread Problem Of Diarrhea In People Living With HIV/AIDS 5/24/2017 10:42:09 AM
Jaguar And Napo Pharmaceuticals, Inc. Issue Commercial Updates 4/6/2017 11:08:44 AM
Jaguar Animal Health And Napo Pharmaceuticals, Inc. Enter Definitive Merger Agreement 3/31/2017 7:49:27 AM
Napo Pharmaceuticals, Inc. Signs Agreement With Alamo Pharma Services To Launch National Sales Force For Mytesi 2/28/2017 7:57:29 AM
Jaguar Animal Health Enters Binding Agreement Of Terms To Merge With Napo Pharmaceuticals, Inc. 2/9/2017 6:22:44 AM
Napo Pharmaceuticals, Inc. Launches Mytesi (Crofelemer) As The Only FDA-Approved Treatment For Relief Of Noninfectious Diarrhea In HIV+ Patients 10/13/2016 7:40:10 AM
Jaguar Animal Health And Napo Pharmaceuticals, Inc. Announce Details For Proposed Merger 10/6/2016 11:52:17 AM